A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I remember when I first purchase this stock at $ 6 something a share and drop to $ 1. it was very downgrade, I thought I made a mistake. So a year later $ 175000 was sitting on my back pocket, that's worth the price. From $ 1 to almost $ 36 a share, that's called trading, with no experience. It's worth the try...